Neurology:青少年儿童脑创伤后,白质病变与行为表现相关

2021-06-21 Freeman MedSci原创

Neurology-青少年儿童脑创伤后,白质病变与行为表现相关

弥散MRI(dMRI)彻底改变了无创地观察白质(WM)通路及其在健康和疾病人群中的行为作用的能力。许多dMRI研究表明,年轻的创伤性脑损伤(TBI)患者在一些纤维束中显示出异常的WM组织,如胼胝体。

这些研究还报告了症状和WM组织减少之间的显著的、中度至高度的相关性,如白质破坏的严重程度增加预示着年轻TBI患者的行为表现较差。

人类大脑在发育过程中的可塑性支持学习和适应,但其隐藏的代价可能是对伤害的脆弱性增加。尽管研究结果很有希望,但这些研究受制于样本量(TBI患者的中位数=21),无法测试有关人口学和临床变量对WM组织影响的具体假设。


ENIGMA (Enhancing NeuroImaging Genetics through Meta-Analysis)是一个世界性的合作分析联盟,它利用大型的联合样本来实现足够的力量来解决开放性问题。目前已经建立了ENIGMA小儿中度/重度创伤性疾病(msTBI)工作组,在此调查了创伤性疾病后的WM微结构改变模式。

由于WM指标的变化在受伤后的第一年可能是动态的,根据以前的出版物和队列的研究设计,研究了WM组织在受伤后三个区间的改变。因此假设,在msTBI组中,WM组织的广泛破坏是明显的,关键的人口统计学因素,如年龄和性别,会对结果产生影响。

藉此,美国University of Utah的Emily L Dennis等人,利用ENIGMA探究了:

(1) 小儿中度-重度创伤者,白质组织受到损伤;
(2) 年龄和性别对受伤后白质组织的影响;
(3) 白质组织与神经行为结果之间的关联。


他们纳入了507名儿童和青少年(244名复杂的轻度至重度TBI[msTBI]和263名对照)。患者被分为三个受伤后的时间段:急性/亚急性-<2个月,后急性-2-6个月,慢性-6个月以上。

在多个区段和所有受伤后的时间间隔内,WM弥散指标都发生了改变。损伤的严重程度是WM改变程度的一个重要因素,但随着损伤后时间的增加,对dMRI测量的差异解释较少。

性别与组别之间存在相互作用:女性创伤性疾病患者的钩状束各向异性(fractional anisotropy)明显低于对照组(𝞫=0.043),这与父母报告的更多行为问题相吻合(𝞫=-0.0027)。

这个研究的重要意义在于发现了,msTBI后的WM破坏是广泛的、持续的,并受人口统计学和临床变量的影响。 

 

 

原文出处:

White Matter Disruption in Pediatric Traumatic Brain Injury: Results from ENIGMA Pediatric Moderate to Severe Traumatic Brain InjuryEmily L Dennis, Karen Caeyenberghs, Kristen R Hoskinson, et al. Neurology May 2021, 10.1212/WNL.0000000000012222; DOI: 10.1212/WNL.0000000000012222

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765874, encodeId=5a211e65874ac, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 08 13:08:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001369, encodeId=af162001369d6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 06 06:08:04 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976226, encodeId=27bc9e62261d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08d45173659, createdName=146e09a9m59暂无昵称, createdTime=Wed Jun 23 14:35:06 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335348, encodeId=06061335348ac, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526567, encodeId=b6e3152656e2d, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765874, encodeId=5a211e65874ac, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 08 13:08:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001369, encodeId=af162001369d6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 06 06:08:04 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976226, encodeId=27bc9e62261d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08d45173659, createdName=146e09a9m59暂无昵称, createdTime=Wed Jun 23 14:35:06 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335348, encodeId=06061335348ac, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526567, encodeId=b6e3152656e2d, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
    2021-11-06 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765874, encodeId=5a211e65874ac, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 08 13:08:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001369, encodeId=af162001369d6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 06 06:08:04 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976226, encodeId=27bc9e62261d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08d45173659, createdName=146e09a9m59暂无昵称, createdTime=Wed Jun 23 14:35:06 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335348, encodeId=06061335348ac, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526567, encodeId=b6e3152656e2d, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
    2021-06-23 146e09a9m59暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1765874, encodeId=5a211e65874ac, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 08 13:08:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001369, encodeId=af162001369d6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 06 06:08:04 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976226, encodeId=27bc9e62261d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08d45173659, createdName=146e09a9m59暂无昵称, createdTime=Wed Jun 23 14:35:06 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335348, encodeId=06061335348ac, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526567, encodeId=b6e3152656e2d, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765874, encodeId=5a211e65874ac, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun May 08 13:08:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001369, encodeId=af162001369d6, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 06 06:08:04 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976226, encodeId=27bc9e62261d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08d45173659, createdName=146e09a9m59暂无昵称, createdTime=Wed Jun 23 14:35:06 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335348, encodeId=06061335348ac, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526567, encodeId=b6e3152656e2d, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Mon Jun 21 12:08:04 CST 2021, time=2021-06-21, status=1, ipAttribution=)]

相关资讯

Sci Adv:科学家创建出可穿透血脑屏障的药物输送纳米系统

在过去的几十年里,研究人员已经确定了导致神经退行性疾病的生物学途径,并开发了很有希望的分子靶向药物。然而,将这些发现转化为临床治疗方法的进展却慢得多,部分原因是将药物运送通过血脑屏障(BBB)是一个巨

JAMA:持续高渗液体治疗对创伤性脑损伤患者神经功能改善无益

在中重度创伤性脑损伤患者中,持续输注20%高渗盐水治疗与标准治疗相比,在6个月时神经功能改善方面无显著差异,持续输注高渗盐水正在改善TBI患者临床功能方法的作用有限

JAMA Neurol:创伤性脑损伤后缺血及血管功能异常的时空变化规律

研究认为缺血是常见的创伤性脑损伤早期症状,部分患者无颅内高血压,并且颈静脉或脑组织氧饱和度存在差异。TBI患者存在明显的病理生理异质性,缺血和充血通常共存,反应映流动-代谢偶联的异常。CBV增高可能与颅内压增高有关,但与CBF/CBV比值异常并存。这些结果强调在处理TBI患者时需要考虑脑血管病理生理的复杂性

Lancet:氨甲环酸用于创伤性脑损伤患者的治疗效果研究

研究认为,氨甲环酸在创伤性脑损伤患者中是安全的,并且在损伤后3小时内治疗可以减少与头部损伤相关的死亡

Neurology:神经丝轻链作为创伤性脑损伤的生物标志物

血清NfL有望作为急性和体育相关脑震荡以及亚急性和慢性TBI患者的生物标志物。

Lancet Neurology:中国创伤性脑损伤患者的临床特征和预后:一项前瞻性、多中心、纵向观察性研究

创伤性脑损伤(TBI)对全球公共卫生提出了巨大的挑战。这种疾病在损伤原因、机制、治疗方法和结果方面的异质性使得它与其他疾病相比是一个非常复杂的问题。